Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dabrafenib + trametinib + nivolumab
- Development stage
- Preclinical
- Lead developer
- Novartis
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This is a combination of three drugs: dabrafenib (a BRAF inhibitor), trametinib (a MEK inhibitor), and nivolumab (a PD-1 inhibitor). While the triple combination is not specifically approved or studied as a single regimen in the provided search results, the components are used in melanoma treatment. The DREAMseq trial studied sequential therapy with nivolumab + ipilimumab followed by dabrafenib + trametinib if necessary, which showed superior overall survival compared to the reverse sequence for patients with BRAF-mutant metastatic melanoma.
- Brand names
- OpdivoTafinlarMekinist
- Other names
- nivolumab + dabrafenibnivolumab + trametinibNivolumab with Dabrafenib and/or Trametinib
02
Targets
BRAF (B-Raf proto-oncogene, serine/threonine kinase)MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on dabrafenib + trametinib + nivolumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dabrafenib + trametinib + nivolumab.